Focused On-demand Library for Zinc finger MYND domain-containing protein 10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O75800

UPID:

ZMY10_HUMAN

Alternative names:

Protein BLu

Alternative UPACC:

O75800; A6NK41; B3KU54; O14570; O75801; Q53FE6; Q8N4R6; Q8NDN6

Background:

Zinc finger MYND domain-containing protein 10, also known as Protein BLu, plays a crucial role in the organization and motility of axonemal structures. It is involved in the pre-assembly of inner and outer dynein arms, essential for the proper building of axonemes for cilia motility. This protein's function is pivotal in ensuring the correct movement and structure of cilia, as suggested by research findings.

Therapeutic significance:

Given its significant role in cilia motility and structure, Zinc finger MYND domain-containing protein 10 is directly associated with Primary Ciliary Dyskinesia, particularly type 22. This condition is characterized by motile cilia abnormalities, leading to severe respiratory infections and potentially situs inversus in Kartagener syndrome. Understanding the role of this protein could pave the way for innovative therapeutic strategies targeting ciliary dysfunctions.